PDCD1 and melanoma: Immune checkpoint inhibitors that target the PD-1 axis form the backbone of systemic treatment for cutaneous malignancies, namely melanoma (1), cutaneous squamous cell carcinoma (cSCC) (2) and Merkel cell carcinoma (3).